Tanvex BioPharma Inc Asset Resilience Ratio
Tanvex BioPharma Inc asset resilience ratio. Tanvex BioPharma Inc (6541) has an Asset Resilience Ratio of 3.85% as of June 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Tanvex BioPharma Inc (6541) liquidity interval to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Tanvex BioPharma Inc (2016–2018)
Asset resilience ratio of Tanvex BioPharma Inc from 2016 to 2018. This chart shows how Tanvex BioPharma Inc's Asset Resilience Ratio has changed over time. Read debt load of Tanvex BioPharma Inc for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Tanvex BioPharma Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see 6541 total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 0% |
| Short-term Investments | NT$130.28 Million | 3.85% |
| Total Liquid Assets | NT$130.28 Million | 3.85% |
Asset Resilience Insights
- Limited Liquidity: Tanvex BioPharma Inc maintains only 3.85% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Tanvex BioPharma Inc Industry Peers by Asset Resilience Ratio
Compare Tanvex BioPharma Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL |
Biotechnology | 1.36% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA |
Biotechnology | 53.11% |
|
Gempharmatech Co. Ltd. A
SHG:688046 |
Biotechnology | 23.95% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 74.48% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
|
Guangdong VTR Bio-Tech Co Ltd
SHE:300381 |
Biotechnology | 4.98% |
Tanvex BioPharma Inc Asset Resilience Ratio by Year (2016–2018)
Tanvex BioPharma Inc asset resilience ratio by year from 2016 to 2018. The table below shows the annual Asset Resilience Ratio data for Tanvex BioPharma Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2018-12-31 | 42.35% | NT$1.90 Billion ≈ $59.75 Million |
NT$4.48 Billion ≈ $141.11 Million |
+15.84pp |
| 2017-12-31 | 26.50% | NT$1.05 Billion ≈ $33.18 Million |
NT$3.97 Billion ≈ $125.17 Million |
-15.17pp |
| 2016-12-31 | 41.67% | NT$1.61 Billion ≈ $50.84 Million |
NT$3.87 Billion ≈ $122.00 Million |
-- |
About Tanvex BioPharma Inc
Tanvex BioPharma, Inc., a pharmaceutical company, engages in the research, development, manufacture, and sale of biosimilar products in Taiwan and the United States. The company focuses on delivering biopharmaceuticals with biosimilars targeting neutropenia, breast cancer, metastatic colorectal cancer, and psoriasis. It also engages in contract development and manufacturing of biological medicine… Read more